These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy. Yun JW; Ahn JB; Kwon E; Ahn JH; Park HW; Heo H; Park JS; Kim H; Paek SH; Kang BC Tissue Eng Regen Med; 2016 Feb; 13(1):100-109. PubMed ID: 30603390 [TBL] [Abstract][Full Text] [Related]
45. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425 [TBL] [Abstract][Full Text] [Related]
46. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614 [TBL] [Abstract][Full Text] [Related]
47. (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Ekesbo A; Andrén PE; Gunne LM; Tedroff J Neuroreport; 1997 Jul; 8(11):2567-70. PubMed ID: 9261828 [TBL] [Abstract][Full Text] [Related]
48. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082 [TBL] [Abstract][Full Text] [Related]
49. Anti-Parkinson effects of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model. Philippens IH; Joosen MJ; Ahnaou A; Andres I; Drinkenburg WP Behav Brain Res; 2014 Aug; 269():81-6. PubMed ID: 24769173 [TBL] [Abstract][Full Text] [Related]
50. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease? Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654 [TBL] [Abstract][Full Text] [Related]
51. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Waters CM; Hunt SP; Jenner P; Marsden CD Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993 [TBL] [Abstract][Full Text] [Related]
52. Effect of selegiline on dopamine concentration in the striatum of a primate. Kaseda S; Nomoto M; Iwata S Brain Res; 1999 Jan; 815(1):44-50. PubMed ID: 9974121 [TBL] [Abstract][Full Text] [Related]
53. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model. Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201 [TBL] [Abstract][Full Text] [Related]
54. Selegiline and the prophylaxis of Parkinson's disease. Sandler M; Willoughby J; Glover V; Gibb C J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604 [TBL] [Abstract][Full Text] [Related]
55. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset. Elliott PJ; Walsh DM; Close SP Neurosci Lett; 1992 Aug; 142(1):1-4. PubMed ID: 1357609 [TBL] [Abstract][Full Text] [Related]
56. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease. Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470 [TBL] [Abstract][Full Text] [Related]
57. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904 [TBL] [Abstract][Full Text] [Related]
58. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors. Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143 [TBL] [Abstract][Full Text] [Related]
59. Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Hikishima K; Ando K; Yano R; Kawai K; Komaki Y; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H Radiology; 2015 May; 275(2):430-7. PubMed ID: 25602507 [TBL] [Abstract][Full Text] [Related]
60. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Russ H; Mihatsch W; Gerlach M; Riederer P; Przuntek H Neurosci Lett; 1991 Feb; 123(1):115-8. PubMed ID: 1712088 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]